EBioMedicine

Scope & Guideline

Elevating scientific collaboration in the life sciences.

Introduction

Welcome to the EBioMedicine information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of EBioMedicine, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2352-3964
PublisherELSEVIER
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2014 to 2024
AbbreviationEBIOMEDICINE / EBioMedicine
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

EBioMedicine aims to advance the field of biomedical research by publishing high-quality studies that contribute to our understanding of disease mechanisms, therapeutic strategies, and preventive measures. The journal emphasizes interdisciplinary research that integrates clinical and translational science, fostering collaboration among researchers, clinicians, and policy makers.
  1. Clinical and Translational Research:
    The journal focuses on studies that bridge the gap between laboratory research and clinical application, highlighting research that leads to the development of new diagnostic tools, treatment strategies, and preventive measures for diseases.
  2. Biomarker Discovery and Validation:
    A significant emphasis is placed on the identification and validation of biomarkers that could aid in disease diagnosis, prognosis, and treatment response, particularly in cancer, infectious diseases, and chronic conditions.
  3. Immunology and Infectious Diseases:
    Research on the immune response to infections, including the development of vaccines and therapeutic interventions, is a core area of focus, especially in the context of emerging infectious diseases like COVID-19.
  4. Genomics and Personalized Medicine:
    The journal publishes studies leveraging genomic data to tailor medical treatments to individual patient profiles, advancing the field of precision medicine across various diseases.
  5. Microbiome Research:
    The role of the microbiome in health and disease, including its impact on metabolic disorders, immune response, and treatment outcomes, is a growing area of interest in the journal.
  6. Novel Therapeutics and Drug Development:
    Studies investigating new therapeutic approaches, including drug repurposing, nanomedicine, and gene therapies, are highlighted, emphasizing innovative strategies to combat diseases.
Recent trends in EBioMedicine reflect a shift toward innovative and multidisciplinary research themes, aligning with current global health challenges and advancements in biomedical science.
  1. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning in research methodologies is increasingly prominent, with studies focusing on predictive modeling, diagnostic algorithms, and personalized treatment strategies.
  2. Long COVID and Post-Acute Sequelae:
    Research addressing the long-term effects of COVID-19, including post-acute sequelae, is rapidly expanding, reflecting the ongoing impact of the pandemic on public health.
  3. Metabolomics and Lipidomics:
    There is a growing focus on metabolomic and lipidomic profiling to understand disease mechanisms and identify biomarkers, particularly in metabolic disorders and cancer.
  4. Immunotherapy and Immune Profiling:
    Studies exploring immunotherapy, including novel approaches and immune profiling for various cancers, are gaining traction, driven by advances in understanding the immune system.
  5. Microbiome-Health Interactions:
    Research on the interactions between the microbiome and various health conditions, including metabolic and autoimmune diseases, is emerging as a significant area of interest.
  6. Genetic and Epigenetic Research:
    The exploration of genetic and epigenetic factors influencing disease susceptibility and treatment response is on the rise, particularly in chronic diseases and cancers.

Declining or Waning

While EBioMedicine has consistently published impactful research, certain themes are showing signs of declining prominence in recent publications. This shift may reflect changes in research focus or evolving scientific priorities.
  1. Traditional Pharmacology:
    Research focusing solely on traditional pharmacological approaches without considering personalized or genomic strategies is becoming less common, as the field moves towards more tailored therapeutic interventions.
  2. Single-Disease Focus:
    There is a noticeable decline in studies that concentrate exclusively on single diseases without considering the broader implications or comorbidities, as interdisciplinary approaches gain traction.
  3. Basic Science Without Clinical Relevance:
    Basic research studies that do not translate into clinical applications or relevance are being overshadowed by studies emphasizing translational impact, as the demand for clinically applicable findings increases.
  4. Static Models of Disease:
    Research using static models that do not account for dynamic biological processes or the complexity of disease interactions is less favored, with a shift towards more comprehensive and integrated modeling approaches.
  5. Conventional Imaging Techniques:
    There is a waning interest in conventional imaging techniques as advanced technologies, including AI-based methods and multimodal imaging, become more prevalent in research design.

Similar Journals

Annual Review of Pathology-Mechanisms of Disease

Exploring the Frontiers of Pathological Research
Publisher: ANNUAL REVIEWSISSN: 1553-4006Frequency: 1 issue/year

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

Med

Bridging Research and Practice for a Healthier Future.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

Science Translational Medicine

Where Science Meets Clinical Practice.
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 1946-6234Frequency: 51 issues/year

Science Translational Medicine is a premier journal published by the American Association for the Advancement of Science, dedicated to bridging the gap between laboratory discovery and clinical application. With an impressive impact factor and a Q1 categorization in the field of Medicine, it is recognized as one of the leading journals, ranking 11 out of 636 in general medicine according to Scopus, placing it in the top 2% of its category. Since its inception in 2009, the journal has been at the forefront of innovative research, presenting high-quality studies that translate scientific advancements into tangible medical solutions. Researchers, professionals, and students alike will find its rich content invaluable for staying informed on cutting-edge developments in the field. The journal's commitment to accessibility ensures that the latest findings and insights are available to a global audience, fostering collaboration and scientific progress.

Journal of Translational Medicine

Empowering Innovation in Biomedical Research.
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

Biomedical Journal

Exploring the Future of Healthcare
Publisher: ELSEVIERISSN: 2319-4170Frequency: 6 issues/year

The Biomedical Journal, published by ELSEVIER, serves as a premier platform for disseminating groundbreaking research in the field of medicine, specifically within the Q1 category of Medicine (Miscellaneous). With the ISSN 2319-4170 and E-ISSN 2320-2890, this Open Access journal has been committed to advancing biomedical science since its inception in 2002. With an impressive Scopus rank of #31 out of 636 in General Medicine and a notable placement in the 95th percentile, the journal provides valuable insights and rigorous studies that contribute significantly to the medical community. Based in the Netherlands at RADARWEG 29, 1043 NX AMSTERDAM, the journal is highly regarded for its timely and diverse range of articles, fostering collaboration and innovation amidst researchers, professionals, and students alike. The ongoing engagement in the journal's converged years from 2012 to 2024 underscores its commitment to keeping pace with the evolving landscape of biomedical research, making it an essential resource for those seeking to stay at the forefront of medical advancements.

Immuno

Fostering Global Collaboration in Immune Research
Publisher: MDPIISSN: Frequency: 4 issues/year

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Current Research in Translational Medicine

Advancing Medical Frontiers Through Innovative Research
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 2452-3186Frequency: 4 issues/year

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

JOURNAL OF MOLECULAR MEDICINE-JMM

Transforming Research into Revolutionary Medical Solutions.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Biomarker Insights

Fostering collaboration in the evolving world of biomarkers.
Publisher: SAGE PUBLICATIONS LTDISSN: 1177-2719Frequency: 1 issue/year

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

CURRENT OPINION IN IMMUNOLOGY

Uncovering Insights in the Immune Landscape
Publisher: CURRENT BIOLOGY LTDISSN: 0952-7915Frequency: 6 issues/year

CURRENT OPINION IN IMMUNOLOGY is a prestigious journal dedicated to the dynamic field of immunology, published by CURRENT BIOLOGY LTD in the United Kingdom. With an ISSN of 0952-7915 and an E-ISSN of 1879-0372, this journal has been a cornerstone of scholarly communication since its inception in 1988 and continues to disseminate cutting-edge research and reviews aimed at advancing our understanding of immune responses. Holding a remarkable Q1 ranking in both Immunology and Allergy categories for 2023, it ranks impressively within the top percentiles in its field, securing 27th233 in Immunology and Allergy and 31st out of 236 in Immunology and Microbiology. Emphasizing high-impact research, the journal provides researchers, professionals, and students with valuable insights into emerging trends and critical developments. As a vital resource in immunological research, it serves as a platform for disseminating innovative findings, fostering collaboration, and enhancing scholarly exchange in a rapidly evolving scientific landscape.